Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 164 | 3.84 |
09:38 ET | 300 | 3.77 |
09:41 ET | 300 | 3.77 |
09:52 ET | 200 | 3.76 |
09:54 ET | 200 | 3.84 |
09:56 ET | 200 | 3.8 |
09:57 ET | 100 | 3.82 |
10:01 ET | 200 | 3.82 |
10:03 ET | 100 | 3.78 |
10:06 ET | 100 | 3.89 |
10:39 ET | 1500 | 3.8 |
10:55 ET | 161 | 3.8 |
11:09 ET | 100 | 3.79 |
11:22 ET | 239 | 3.78 |
11:26 ET | 300 | 3.76 |
11:27 ET | 100 | 3.87 |
11:31 ET | 400 | 3.89 |
11:33 ET | 2700 | 3.82 |
11:38 ET | 200 | 3.9 |
11:40 ET | 100 | 3.9 |
11:42 ET | 164 | 3.9 |
11:56 ET | 100 | 3.835 |
12:05 ET | 268 | 3.825 |
12:34 ET | 400 | 3.84 |
12:56 ET | 200 | 3.85 |
01:03 ET | 1764 | 3.9 |
01:33 ET | 100 | 3.825 |
01:37 ET | 1336 | 3.82 |
01:42 ET | 100 | 3.77 |
02:02 ET | 600 | 3.75 |
02:20 ET | 600 | 3.755 |
02:29 ET | 100 | 3.75 |
02:36 ET | 100 | 3.7322 |
02:38 ET | 513 | 3.72 |
02:40 ET | 1100 | 3.71 |
02:44 ET | 100 | 3.66 |
02:58 ET | 300 | 3.68 |
03:03 ET | 200 | 3.74 |
03:16 ET | 200 | 3.73 |
03:30 ET | 400 | 3.74 |
03:36 ET | 200 | 3.74 |
03:41 ET | 148 | 3.76 |
03:48 ET | 200 | 3.81 |
03:56 ET | 100 | 3.82 |
03:59 ET | 5445 | 3.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 221.4M | -2.1x | --- |
Rezolute Inc | 219.9M | -3.5x | --- |
ATAI Life Sciences NV | 221.0M | -5.7x | --- |
Omeros Corp | 218.4M | -1.4x | --- |
Candel Therapeutics Inc | 225.6M | -5.7x | --- |
Pyxis Oncology Inc | 226.7M | -2.7x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $214.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.